Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Intellia Therapeutics (NTLA) over the last 10 years, with Q3 2025 value amounting to $11.1 million.

  • Intellia Therapeutics' Non-cash Items rose 17203.97% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 17203.97%. This contributed to the annual value of $4.2 million for FY2024, which is 8817.82% down from last year.
  • Per Intellia Therapeutics' latest filing, its Non-cash Items stood at $11.1 million for Q3 2025, which was up 17203.97% from $4.2 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Non-cash Items ranged from a high of $493.0 million in Q4 2021 and a low of $2.0 million during Q3 2021
  • In the last 5 years, Intellia Therapeutics' Non-cash Items had a median value of $4.3 million in 2024 and averaged $74.6 million.
  • In the last 5 years, Intellia Therapeutics' Non-cash Items soared by 1660798.74% in 2021 and then tumbled by 9934.75% in 2022.
  • Intellia Therapeutics' Non-cash Items (Quarter) stood at $493.0 million in 2021, then crashed by 99.35% to $3.2 million in 2022, then soared by 1016.73% to $35.9 million in 2023, then tumbled by 88.18% to $4.2 million in 2024, then skyrocketed by 162.44% to $11.1 million in 2025.
  • Its Non-cash Items stands at $11.1 million for Q3 2025, versus $4.2 million for Q2 2025 and $4.5 million for Q1 2025.